169 related articles for article (PubMed ID: 9021195)
1. A cytotoxicity assay for evaluation of candidate anti-Pneumocystis carinii agents.
Cushion MT; Chen F; Kloepfer N
Antimicrob Agents Chemother; 1997 Feb; 41(2):379-84. PubMed ID: 9021195
[TBL] [Abstract][Full Text] [Related]
2. Use of an ATP bioluminescent assay to evaluate viability of Pneumocystis carinii from rats.
Chen F; Cushion MT
J Clin Microbiol; 1994 Nov; 32(11):2791-800. PubMed ID: 7852574
[TBL] [Abstract][Full Text] [Related]
3. In vitro pharmacodynamic parameters of sordarin derivatives in comparison with those of marketed compounds against Pneumocystis carinii isolated from rats.
Aviles P; Aliouat EM; Martinez A; Dei-Cas E; Herreros E; Dujardin L; Gargallo-Viola D
Antimicrob Agents Chemother; 2000 May; 44(5):1284-90. PubMed ID: 10770763
[TBL] [Abstract][Full Text] [Related]
4. Activity of terbinafine against Pneumocystis carinii in vitro and its efficacy in the treatment of experimental pneumonia.
Contini C; Manganaro M; Romani R; Tzantzoglou S; Poggesi I; Vullo V; Delia S; De Simone C
J Antimicrob Chemother; 1994 Nov; 34(5):727-35. PubMed ID: 7706168
[TBL] [Abstract][Full Text] [Related]
5. Highly active anti-Pneumocystis carinii compounds in a library of novel piperazine-linked bisbenzamidines and related compounds.
Cushion MT; Walzer PD; Collins MS; Rebholz S; Vanden Eynde JJ; Mayence A; Huang TL
Antimicrob Agents Chemother; 2004 Nov; 48(11):4209-16. PubMed ID: 15504843
[TBL] [Abstract][Full Text] [Related]
6. Effects of atovaquone and diospyrin-based drugs on the cellular ATP of Pneumocystis carinii f. sp. carinii.
Cushion MT; Collins M; Hazra B; Kaneshiro ES
Antimicrob Agents Chemother; 2000 Mar; 44(3):713-9. PubMed ID: 10681344
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo activity of iclaprim, a diaminopyrimidine compound and potential therapeutic alternative against Pneumocystis pneumonia.
Aliouat EM; Dei-Cas E; Gantois N; Pottier M; Pinçon C; Hawser S; Lier A; Huang DB
Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):409-415. PubMed ID: 29330709
[TBL] [Abstract][Full Text] [Related]
8. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
Warnock AC; Rimland D
Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
[TBL] [Abstract][Full Text] [Related]
9. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329.
Schmatz DM; Powles M; McFadden DC; Pittarelli LA; Liberator PA; Anderson JW
J Protozool; 1991; 38(6):151S-153S. PubMed ID: 1818147
[TBL] [Abstract][Full Text] [Related]
10. Dicationic diarylfurans as anti-Pneumocystis carinii agents.
Boykin DW; Kumar A; Spychala J; Zhou M; Lombardy RJ; Wilson WD; Dykstra CC; Jones SK; Hall JE; Tidwell RR
J Med Chem; 1995 Mar; 38(6):912-6. PubMed ID: 7699707
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Pneumocystis carinii pneumonia in patients with AIDS.
Wordell CJ; Hauptman SP
Clin Pharm; 1988 Jul; 7(7):514-27. PubMed ID: 3138063
[TBL] [Abstract][Full Text] [Related]
12. Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents.
Kovacs JA; Allegra CJ; Beaver J; Boarman D; Lewis M; Parrillo JE; Chabner B; Masur H
J Infect Dis; 1989 Aug; 160(2):312-20. PubMed ID: 2527275
[TBL] [Abstract][Full Text] [Related]
13. Analogs of pentamidine as potential anti-Pneumocystis chemotherapeutics.
Maciejewska D; Zabinski J; Kaźmierczak P; Rezler M; Krassowska-Świebocka B; Collins MS; Cushion MT
Eur J Med Chem; 2012 Feb; 48():164-73. PubMed ID: 22200403
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of caspofungin, a 1,3-β-D-glucan synthase inhibitor, on Pneumocystis carinii pneumonia in rats.
Sun P; Tong Z
Med Mycol; 2014 Nov; 52(8):798-803. PubMed ID: 25288652
[TBL] [Abstract][Full Text] [Related]
15. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro.
Cushion MT; Stanforth D; Linke MJ; Walzer PD
Antimicrob Agents Chemother; 1985 Dec; 28(6):796-801. PubMed ID: 3936409
[TBL] [Abstract][Full Text] [Related]
16. A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation.
Colby C; McAfee S; Sackstein R; Finkelstein D; Fishman J; Spitzer T
Bone Marrow Transplant; 1999 Oct; 24(8):897-902. PubMed ID: 10516703
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients.
Bucher HC; Griffith L; Guyatt GH; Opravil M
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Jun; 15(2):104-14. PubMed ID: 9241108
[TBL] [Abstract][Full Text] [Related]
18. Standardization of an in vitro drug screening assay by use of cryopreserved and characterized Pneumocystis carinii populations.
Collins MS; Cushion MT
J Eukaryot Microbiol; 2001; Suppl():178S-179S. PubMed ID: 11906052
[No Abstract] [Full Text] [Related]
19. Pneumocystis carinii dihydropteroate synthase but not dihydrofolate reductase gene mutations correlate with prior trimethoprim-sulfamethoxazole or dapsone use.
Ma L; Borio L; Masur H; Kovacs JA
J Infect Dis; 1999 Dec; 180(6):1969-78. PubMed ID: 10558954
[TBL] [Abstract][Full Text] [Related]
20. Effects of sterol inhibitors on the ATP content of Pneumocystis carinii.
Kaneshiro ES; Collins M; Cushion MT
J Eukaryot Microbiol; 1999; 46(5):142S-143S. PubMed ID: 10519292
[No Abstract] [Full Text] [Related]
[Next] [New Search]
